Correlation Between Crinetics Pharmaceuticals and Mink Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Crinetics Pharmaceuticals and Mink Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crinetics Pharmaceuticals and Mink Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crinetics Pharmaceuticals and Mink Therapeutics, you can compare the effects of market volatilities on Crinetics Pharmaceuticals and Mink Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crinetics Pharmaceuticals with a short position of Mink Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crinetics Pharmaceuticals and Mink Therapeutics.

Diversification Opportunities for Crinetics Pharmaceuticals and Mink Therapeutics

0.18
  Correlation Coefficient

Average diversification

The 3 months correlation between Crinetics and Mink is 0.18. Overlapping area represents the amount of risk that can be diversified away by holding Crinetics Pharmaceuticals and Mink Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mink Therapeutics and Crinetics Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crinetics Pharmaceuticals are associated (or correlated) with Mink Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mink Therapeutics has no effect on the direction of Crinetics Pharmaceuticals i.e., Crinetics Pharmaceuticals and Mink Therapeutics go up and down completely randomly.

Pair Corralation between Crinetics Pharmaceuticals and Mink Therapeutics

Given the investment horizon of 90 days Crinetics Pharmaceuticals is expected to under-perform the Mink Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Crinetics Pharmaceuticals is 3.16 times less risky than Mink Therapeutics. The stock trades about -0.06 of its potential returns per unit of risk. The Mink Therapeutics is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  72.00  in Mink Therapeutics on October 6, 2024 and sell it today you would earn a total of  17.00  from holding Mink Therapeutics or generate 23.61% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Crinetics Pharmaceuticals  vs.  Mink Therapeutics

 Performance 
       Timeline  
Crinetics Pharmaceuticals 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Crinetics Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Crinetics Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.
Mink Therapeutics 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Mink Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady forward-looking signals, Mink Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Crinetics Pharmaceuticals and Mink Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Crinetics Pharmaceuticals and Mink Therapeutics

The main advantage of trading using opposite Crinetics Pharmaceuticals and Mink Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crinetics Pharmaceuticals position performs unexpectedly, Mink Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mink Therapeutics will offset losses from the drop in Mink Therapeutics' long position.
The idea behind Crinetics Pharmaceuticals and Mink Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Complementary Tools

Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Stocks Directory
Find actively traded stocks across global markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets